| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/24/2006 | US6989147 Tumor necrosis factor receptor protein for use in the treatment of arthritis |
| 01/24/2006 | US6989143 Depletion method of blood plasma ascorbate |
| 01/24/2006 | CA2433366C Amlodipine free base |
| 01/24/2006 | CA2339353C Fast dissolving orally consumable films |
| 01/24/2006 | CA2327325C Stimulus sensitive gel with radioisotope and methods of making |
| 01/24/2006 | CA2320259C Bioactive agent release coating |
| 01/24/2006 | CA2248576C Method of forming articles and patterning surfaces via capillary micromolding |
| 01/24/2006 | CA2150399C Incorporation of a water-soluble active principle in a lipid |
| 01/24/2006 | CA2119250C Blended lipid vesicles |
| 01/23/2006 | CA2513024A1 Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them |
| 01/23/2006 | CA2475736A1 Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them |
| 01/19/2006 | WO2006007354A2 A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device |
| 01/19/2006 | WO2006007332A1 Oral delivery of peptide pharmaceutical compositions |
| 01/19/2006 | WO2006007261A1 Photo-triggered release of active substances from dendrimer-photosensitizer complexes |
| 01/19/2006 | WO2006007183A1 Binary thermo-gelling composition |
| 01/19/2006 | WO2006006929A1 Infusion and injection solution of levodopa |
| 01/19/2006 | WO2006006861A1 Composition and method for medical imaging of body cavities |
| 01/19/2006 | WO2006006603A1 Liposome allowing the discharge of substance entrapped therein from endosome |
| 01/19/2006 | WO2006006577A1 Loxoprofen-containing composition for oral administration |
| 01/19/2006 | WO2006005910A2 Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose |
| 01/19/2006 | WO2006005853A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 01/19/2006 | WO2006005845A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 01/19/2006 | WO2006005844A1 Pressurized foaming composition for topical treatment of psoriasis |
| 01/19/2006 | WO2006005843A1 Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology |
| 01/19/2006 | WO2006005759A2 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | WO2006005667A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 01/19/2006 | WO2006005621A2 Method for producing albumen/corticoid conjugates |
| 01/19/2006 | WO2005105140A3 Meningococcal conjugate vaccination |
| 01/19/2006 | WO2005102307A3 Beneficial effects of increasing local blood flow |
| 01/19/2006 | WO2005082379A8 Myocardial perfusion imaging using adenosine receptor agonists |
| 01/19/2006 | WO2005009408A3 Sustained release dosage forms of anesthetics for pain management |
| 01/19/2006 | WO2004028472A3 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
| 01/19/2006 | US20060015054 External plaster containing 4-biphenylacetic acid |
| 01/19/2006 | US20060014839 Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction |
| 01/19/2006 | US20060014834 For treatment of skin disorders (acne); solubilized in alcohol |
| 01/19/2006 | US20060014788 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/19/2006 | US20060014734 Immediate release pharmaceutical formulation |
| 01/19/2006 | US20060014730 Ansamycin formulations and methods for producing and using same |
| 01/19/2006 | US20060014712 Controlled delivery of therapeutic compounds |
| 01/19/2006 | US20060014699 Aqueous pharmaceutical formulaton comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism |
| 01/19/2006 | US20060014695 Hpma-polyamine conjugates and uses therefore |
| 01/19/2006 | US20060014692 Methods of using non-human animal Apoliprotein A-I protein |
| 01/19/2006 | US20060014687 Bone delivery conjugates and method of using same to target proteins to bone |
| 01/19/2006 | US20060014672 Tumor specific oligosaccharide epitopes and use thereof |
| 01/19/2006 | US20060014666 Water-solubility macromolecule conjugate with interferon; polyoxyethylene glycol, polyoxypropylene glycol or copolymers; one end group having a glucose attached, the other an interferon; long physiological cycle half-life; bioavailability; binds to asialoglycoprotein receptors on liver; hepititis B/C |
| 01/19/2006 | US20060014665 Therapeutic agent |
| 01/19/2006 | US20060014256 Sodium chondroitin sulfate, chondroitin-sulfate-containing material and processes for producing the same |
| 01/19/2006 | US20060014254 Albumin fusion proteins |
| 01/19/2006 | US20060014245 Immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain prepared and retain the ability to specifically bind antigen; cancer |
| 01/19/2006 | US20060014201 Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| 01/19/2006 | US20060013896 Methods of treating acute pain using diclofenac |
| 01/19/2006 | US20060013895 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes |
| 01/19/2006 | US20060013883 Poloxamer and poloxamine compositions for nucleic acid delivery |
| 01/19/2006 | US20060013882 Tri-block copolymers for nanosphere-based drug delivery |
| 01/19/2006 | US20060013879 Gel composition and methods |
| 01/19/2006 | US20060013877 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 01/19/2006 | US20060013872 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | US20060013861 Functional foods comprising flavonoids and tocotrienols and methods thereof |
| 01/19/2006 | US20060013860 Anticancer agents; side effect reduction |
| 01/19/2006 | US20060013851 Therapeutic polyanhydride compounds for drug delivery |
| 01/19/2006 | US20060013836 Dissolving ixabepilone in tert-butanol and water, and then vacuum drying to lypophilize; 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-7-oxabicyclo[14.1.0]heptadecane-5,9-dione is ixabepilone |
| 01/19/2006 | US20060013834 Room temperature stable aqueous liquid pharmaceutical composition |
| 01/19/2006 | US20060013826 Recombinant measles viruses expressing epitopes of antigens of RNA viruses - use for the preparation of vaccine compositions |
| 01/19/2006 | US20060013820 Antigen delivery vectors and constructs |
| 01/19/2006 | US20060013813 Proteins and nucleic acids encoding same |
| 01/19/2006 | US20060013800 Stable immunogenic product comprising antigenic heterocomplexes |
| 01/19/2006 | US20060013797 N-maleimidyl polymer derivatives |
| 01/19/2006 | DE10247755B4 Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine Selective, local activation of members of the TNF receptor family by systemically inactive non-antibody-TNF-ligand fusion proteins |
| 01/19/2006 | DE102004032051A1 Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform A process for preparing a secured against abuse, solid dosage form |
| 01/19/2006 | DE102004031325A1 Wirkstoffhaltige feste Formkörper zur äußerlichen Anwendung gegen Parasiten an Tieren Active ingredient-containing solid moldings for external use against parasites on animals |
| 01/19/2006 | DE102004031158A1 Verwendung von Ethergruppen enthaltenden Polymeren als Lösungsvermittler Use of ether containing polymers as solubilizers |
| 01/19/2006 | DE102004016779A1 Drospirenonhaltige Zubereitungen zur transdermalen Anwendung Drospirenonhaltige formulations for transdermal application |
| 01/19/2006 | CA2574437A1 Infusion and injection solution of levodopa |
| 01/19/2006 | CA2573605A1 Method for producing albumen/corticoid conjugates |
| 01/19/2006 | CA2573456A1 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | CA2572915A1 Pharmaceutical composition containing botulinum neurotoxin |
| 01/19/2006 | CA2572770A1 Polypeptide protracting tags comprising a tetrazole moiety |
| 01/19/2006 | CA2571739A1 A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| 01/19/2006 | CA2571554A1 A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device |
| 01/19/2006 | CA2570311A1 Oral delivery of peptide pharmaceutical compositions |
| 01/19/2006 | CA2568993A1 S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor |
| 01/19/2006 | CA2567742A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 01/19/2006 | CA2567687A1 Pressurized foaming composition for topical treatment of psoriasis |
| 01/19/2006 | CA2567682A1 Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology |
| 01/19/2006 | CA2553436A1 Peptides selectively lethal to malignant and transformed mammalian cells |
| 01/18/2006 | EP1616957A1 Vector |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616574A1 Receptor specific transepithelial transport of therapeutics |
| 01/18/2006 | EP1616573A2 Adjuvants for use in vaccines |
| 01/18/2006 | EP1616563A2 Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases |
| 01/18/2006 | EP1616562A1 Novel preparation and administration form comprising an acid-labile active compound |
| 01/18/2006 | EP1616561A1 Antidiabetic preparation for oral administration |
| 01/18/2006 | EP1616182A2 Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 |
| 01/18/2006 | EP1616005A1 Di-glycosyl-glyceryl compounds for the stabilisation and preservation of biomaterials |
| 01/18/2006 | EP1615995A2 Morpholino imaging and therapy via amplification targeting |
| 01/18/2006 | EP1615874A1 New non-ionic surfactants for solubilizing poorly soluble molecules |
| 01/18/2006 | EP1615668A1 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy |
| 01/18/2006 | EP1615665A2 Delivery of immune response modifier compounds |
| 01/18/2006 | EP1615650A1 Phosphate derivatives of pharmaceutical products |